Back
PERAO
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
๐ฆ๐บ ASX
๐ Overview
๐ Performance
๐ต Cost
๐ Esg
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
N/A
Annual Growth
5 years average annual capital growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
4
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
Percheron Therapeutics Limited - Option Expiring 20-May-2028 Deferred
๐ Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in PERAO
4
๐ Total Capital Earnings
N/A
๐ Average investment frequency
N/A
๐ต Average investment amount
N/A
โฐ Last time a customer invested in PERAO
N/A
PERAO investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
50%
50k - 100k
Less than 50k
50%
๐ถ Age of investors
18 - 25
26 - 34
25%
35 - 90
75%
๐ Legal gender of investors
Female
Male
100%
Pearlers who invest in PERAO also invest in...
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Companyโs products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
๐ Performance (5Yr p.a)
-17.14%
๐ Share price
$0.01 AUD
๐ฆ LOGISTICS
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
๐ Performance (5Yr p.a)
20.30%
๐ Share price
$49.75 AUD
๐ HIGH PRICE GROWTH
๐ค TECHNOLOGY
๐บ๐ธ UNITED STATES
RBTZ.AX was created on 2018-09-12 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. ๏ปฟRBTZ.AX aims to track the performance of an index (before fees and expenses) that includes global companies involved in the production or use of robotics and artificial intelligence (A.l.) products and services.
๐ Performance (5Yr p.a)
4.32%
๐ Share price
$13.69 AUD
๐ค TECHNOLOGY
๐ฆ๐บ EX AUSTRALIA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
15.99%
๐ Share price
$139.40 AUD
๐ GLOBAL
๐ค TECHNOLOGY
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as โClimate Leadersโ that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
๐ Performance (5Yr p.a)
8.97%
๐ Share price
$15.47 AUD
๐ GLOBAL
๐ค TECHNOLOGY
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
Want more shares? Try these...
Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Companyโs products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
๐ Performance (5Yr p.a)
-17.14%
๐ Share price
$0.01 AUD
๐ฆ LOGISTICS